How to Get Tirzepatide Through Telehealth in 2026

Tirzepatide is the dual GIP/GLP-1 receptor agonist behind Zepbound and Mounjaro — and it's emerged as the most effective weight loss medication currently available. Clinical trials show average weight loss of 20–25% of body weight at the highest dose, compared to 15–17% for semaglutide. Getting it through telehealth in 2026 is straightforward, but there are important distinctions to understand.

Brand-Name vs. Compounded Tirzepatide

FDA-approved tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) is available at retail pharmacies with a prescription. List price is approximately $1,000 per month, though manufacturer savings cards can reduce this significantly. Eli Lilly's savings program offers Zepbound at reduced pricing for cash-pay patients.

Compounded tirzepatide is available through some telehealth platforms at significantly lower prices — typically $199–400 per month depending on dose and provider. However, the regulatory landscape for compounded tirzepatide is shifting rapidly.

Telehealth Platforms Offering Tirzepatide

Not all GLP-1 telehealth platforms offer tirzepatide — many focus exclusively on semaglutide due to lower compounding costs and longer market track record. Platforms that do offer tirzepatide typically charge more than their semaglutide programs.

Who Should Consider Tirzepatide Over Semaglutide

Tirzepatide may be preferable if you've plateaued on semaglutide and need stronger appetite suppression, if you have type 2 diabetes (tirzepatide has shown superior A1C reduction), if you tolerate GIP-pathway stimulation well, or if your weight loss goals require the additional efficacy that dual-agonism provides.

Semaglutide may be preferable if you're just starting GLP-1 therapy and want to try the medication with the longest safety track record, if cost is a primary concern (compounded semaglutide is typically cheaper), or if your provider recommends it based on your specific clinical profile.

The Titration Difference

Tirzepatide uses a different titration schedule than semaglutide. The standard escalation for Zepbound starts at 2.5mg weekly for 4 weeks, then 5mg, 7.5mg, 10mg, 12.5mg, and up to 15mg — with at least 4 weeks at each dose before increasing. Side effects, particularly GI-related, tend to be slightly more pronounced at each dose escalation compared to semaglutide.

Compounded tirzepatide may use different titration schedules depending on the formulation. Your provider should outline a clear titration plan specific to the compounded product they're prescribing.

Oral Tirzepatide: What's Coming

Eli Lilly's oral tirzepatide (Foundayo, or orforglipron) received FDA approval and is now available at select pharmacies. Unlike injectable tirzepatide, the oral version is a daily pill. Manufacturer savings cards bring the cost to $149/month for the starting dose. This option is only available as a brand-name FDA-approved product — there are no compounded oral tirzepatide alternatives.